Trial Profile
A Single Center, Preliminary Study Assessing the Real Life Effects of Ruxolitinib in Hydroxyurea Resistant or Intolerant Polycythemia Vera Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2018 New trial record